4 completed, 4 recruiting, 2 terminated, 1 unknown. 8 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Recruiting 3, Unknown 1 |
| Phase 3 | 2 | Terminated 2 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow senicapoc: new trials by email Literature Review of senicapoc trials Research Report on senicapoc
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia | Phase 2 | Recruiting | Biossil Inc. | 105 | 2026-08-13 | 2026-08-17 |
| Senicapoc and Perampanel for Newly Diagnosed Glioblastoma senicapoc, Perampanel - Glioblastoma | Early Phase 1 | Recruiting | Aarhus University Hospital | 36 | 2026-03-01 | 2026-05-07 |
| Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease Senicapoc, Placebo - Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis | Phase 2 | Recruiting | Vejle Hospital | 140 | 2025-08-01 | 2026-05-07 |
| Senicapoc in Alzheimer's Disease Senicapoc, Placebo Tablet - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Recruiting | University of California, Davis | 55 | 2022-03-18 | 2026-08-17 |
| Senicapoc and Dehydrated Stomatocytosis Senicapoc (synonyms: ICA-17043; 2,2-bis-(4-fluorophenyl)-2-phenylacetamide) - Dehydrated Hereditary Stomatocytosis | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 5 | 2021-04-15 | 2024-02-22 |
| Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency Senicapoc - ARDS, Human, COVID | Phase 2 | Unknown | University of Aarhus | 46 | 2020-04-24 | 2020-10-20 |
| Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma senicapoc, Placebo - Exercise Induced Asthma | Phase 2 | Completed | Icagen | 69 | 2009-03-01 | 2011-07-14 |
| Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects senicapoc, Placebo - Atopic Asthma | Phase 2 | Completed | Icagen | 34 | 2008-10-01 | 2011-07-14 |
| A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy ICA-17043 - Sickle Cell Disease, Sickle Cell Anemia | Phase 3 | Terminated | Icagen | 51 | 2006-02-01 | 2007-09-11 |
| A Stratified Sickle Event Randomized Trial (ASSERT) ICA-17043 - Sickle Cell Disease | Phase 3 | Terminated | Icagen | 297 | 2005-02-01 | 2008-03-27 |
| A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia. Low Dose ICA-17043, High dose ICA-17043, Placebo - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Completed | Icagen | 90 | 2002-02-01 | 2011-07-18 |
Anemia, Sickle Cell (4) · Anemia (2) · Inflammation (2) · Alzheimer Disease (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Asthma (1) · Asthma, Exercise-Induced (1) · Bronchial Spasm (1) · Cognitive Dysfunction (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Coronavirus Infections (1) · Genetic Diseases, Inborn (1) · Glioblastoma (1) · Hematologic Diseases (1)
Icagen (5) · Aarhus University Hospital (1) · Biossil Inc. (1) · Boston Children's Hospital (1) · University of Aarhus (1) · University of California, Davis (1) · Vejle Hospital (1)
United States (6) · Denmark (3) · United Kingdom (3) · Brazil (1) · Canada (1) · Estonia (1) · France (1) · Jamaica (1) · Trinidad and Tobago (1)
Asger Granfeldt, MD, PhD (1) · Bodil S Rasmussen, MD, PhD (1) · Carlo Brugnara, MD (1) · John Olichney, MD (1) · Jonathan W Stocker, Ph.D. (1) · Jonathan W Stocker, PhD (1) · Jonathon Stocker, Ph.D. (1) · Kenneth I Ataga, MD (1) · Klaus T Kristiansen, MD (1) · Ole Hilberg, Proffesor (1) · Steffen Christensen, MD (1) · Tak H Lee, FRCP (1)
2025 (1)